Compare Firy Inc. (FIRY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Tango Therapeutics Inc. — how do they compare? Firy Inc. trades at $11.15 (market cap $185.67M), while Tango Therapeutics Inc. trades at $22.66 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is far larger — about 20.1× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and Tango Therapeutics Inc. for 0 Days on average.
| FIRY | TNGX | |
|---|---|---|
Market Cap | $185.67M | $3.74B |
Volume | 194,374 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $13.10 | $32.90 |
52-Week Low | $2.28 | $7.50 |
Typical Hold Time | 13 Days | 0 Days |
Enterprise Value | $154.27M | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY trades at $12.41, up 0.16% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $31.0 million but missed EPS expectations with a net loss. Despite a $719 million legal victory against Papaya Gaming, cash burn remains high with negative operating cash flow of -$69 million in 2025. The stock shows mixed analyst sentiment with 60% hold ratings.
The outlook remains challenging with persistent losses and negative margins, though the legal win provides potential upside. Key risks include ongoing cash burn and execution uncertainty. Investors should weigh the litigation recovery potential against fundamental weakness in the core business.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
